Current measures of anticancer drug efficacy reflect bulk cell killing and are poorly suited to detect activity against cancer stem cells (CSCs), which sustain tumor growth. The CSC paradigm necessitates a reexamination of methodologies used to evaluate clinical efficacy of anticancer therapies, as well as strategies employed during preclinical drug development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据